Sonke Lamivudine 150 Tablets 150mg FC tablet
PDF Leaflet Revision Date: 25 Jan 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Part of antiretroviral combination therapy for HIV treatment.
Dosage (summary)
300 mg daily; 150 mg twice daily or 300 mg once daily for adults.
Special Populations
- Renal impairment
- Hepatic impairment
- Children < 3 months
Pregnancy & Breastfeeding
Use in pregnancy if clinically needed; avoid breastfeeding to prevent HIV transmission.
Key Drug Interactions
- Increased lamivudine levels with trimethoprim
- Not recommended with zalcitabine or other cytidine analogues
Contraindications
- Hypersensitivity to lamivudine
Common side effects
- Peripheral neuropathy
- Pancreatitis
- Skin rash
- Lactic acidosis
Counselling Points
- Monitor for signs of lactic acidosis
- Continue precautions to prevent HIV transmission
- Seek medical advice for joint pain or stiffness
Serious warnings
- Risk of lactic acidosis
- Not recommended as monotherapy
- Opportunistic infections may occur
Important Disclaimer
The Sonke Lamivudine 150 Tablets 150mg FC tablet professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
